| 17.55 0.55 (3.24%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.39 | 1-year : | 24.99 |
| Resists | First : | 18.32 | Second : | 21.39 |
| Pivot price | 15.2 |
|||
| Supports | First : | 14.45 | Second : | 12.06 |
| MAs | MA(5) : | 17.39 |
MA(20) : | 14.62 |
| MA(100) : | 15.66 |
MA(250) : | 17.04 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 84.2 |
D(3) : | 87.7 |
| RSI | RSI(14): 66.9 |
|||
| 52-week | High : | 29.22 | Low : | 12.06 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SMMT ] has closed below upper band by 17.7%. Bollinger Bands are 47.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.72 - 17.8 | 17.8 - 17.88 |
| Low: | 16.93 - 17.03 | 17.03 - 17.12 |
| Close: | 17.4 - 17.56 | 17.56 - 17.69 |
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Fri, 11 Sep 2026
Why Is SMMT Stock Tumbling Today? - Stocktwits
Wed, 09 Sep 2026
Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Tue, 08 Sep 2026
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab - Yahoo Finance
Mon, 07 Sep 2026
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Mon, 07 Sep 2026
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Thu, 03 Sep 2026
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 798 (M) |
| Shares Float | 152 (M) |
| Held by Insiders | 80.8 (%) |
| Held by Institutions | 17.4 (%) |
| Shares Short | 37,430 (K) |
| Shares Short P.Month | 37,330 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -101.7 % |
| Return on Equity (ttm) | -192.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -458 (M) |
| Levered Free Cash Flow | -140 (M) |
| PE Ratio | -15.82 |
| PEG Ratio | 0 |
| Price to Book value | 22.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -30.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|